FAScinate Therapeutics

Executive Summary

FAScinate Therapeutics is a privately held biopharmaceutical company based in Cambridge, Massachusetts, focused on developing disease-modifying therapies for neurodegenerative disorders. Its lead candidate, KM-819, is a small molecule designed to slow or halt the progression of Parkinson's disease (PD) and multiple system atrophy (MSA). Unlike current symptomatic treatments, KM-819 targets the underlying disease pathology, offering potential hope for millions of patients worldwide. The company was founded in 2018 and is actively advancing its preclinical and early clinical programs. While specific financing details and clinical stage are undisclosed, the company's focused approach on a high-unmet medical need positions it as a potential player in the neurodegenerative space. Key upcoming catalysts include the initiation of Phase 1 clinical trials, which would represent a major milestone, as well as potential collaborations with larger pharmaceutical companies to support further development. Additionally, the company may seek to present preclinical or early clinical data at major medical conferences to attract investor interest. The success of KM-819 and the company's overall strategy depend on demonstrating safety and tolerability in humans, as well as securing sufficient funding to support continued development. FAScinate Therapeutics represents an early-stage but scientifically compelling opportunity in the neurodegenerative disease landscape.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for KM-819 in Parkinson's Disease70% success
• Q2 2026Presentation of Preclinical Data at a Major Neurology Conference (e.g., AAN, MDS)80% success
• H1 2027Announcement of a Strategic Partnership or Licensing Agreement40% success